Many papers document that kinase inhibitors display cardiotoxicity. Molecular mechanism can be different for each inhibitor and may include also interaction with off-targets like herG.

http://www.ncbi.nlm.nih.gov/pubmed/21283106

Arvind, could you specific the context for your question?

Regarding the pharmaceutical industries effords to make safe drugs, hERG inhibition was considered to be a predictive biomarker for life threatening Torsade-de-Pointes left ventricular arrhythmias since the hERG channel is the major repolarising component during the action potental of cardiomyocytes.

In the context of anti-cancer drug developement, protein kinase inhibitors are still in the focus ot the pharma industry because they can be used to to arrest or kill cancer cells. Some of the older and less specific inhibitors have severe cardiac side effects due to cardiac cytotoxicity as mentioned by Helena. This has nothing to do with the hERG channel block (activity). But it was found that potassium channels (especially the hERG channel) are upregulated in cancer cells. Unfortunately, I am not too much into the matter of oncology but maybe there exist comparisons in the potency of hERG blockers and protein kinase inhibitors to arrest or kill cancer cells.

Here you can find a link to an abstract of an article concerning the rule of hERG the channel in cancer cells:

http://www.ncbi.nlm.nih.gov/pubmed/23970866

Best regards,

Ralf